

rESWT & Injection for myofascial pain measured with Elastic index

1 Original Research

2 **Effects of Radial Extracorporeal Shockwave Therapy**
3 **Versus 1% Lidocaine Injection for Myofascial Trigger**
4 **Points Measured with Elastic Index**

5 Areerat SUPUTTITADA^{1*}, Carl PC CHEN², Narin
6 NGAMRUNGSIRI¹, Christoph SCHMITZ³

7 ¹Department of Rehabilitation Medicine, Faculty of Medicine,
8 Chulalongkorn University, and King Chulalongkorn Memorial
9 Hospital, Bangkok, Thailand

10 ²Department of Physical Medicine and Rehabilitation, Chang
11 Gung Memorial Hospital at Linkou and College of Medicine,

rESWT & Injection for myofascial pain measured with Elastic index

1 Chang Gung University, Guishan District, Taoyuan City, Taiwan

2 ³ Department of Anatomy II, Ludwig-Maximilians-University of

3 Munich, Munich, Germany

4 * Correspondence: Professor Areerat Suputtitada, MD.

5 Department of Rehabilitation Medicine, Faculty of Medicine,

6 Chulalongkorn University, and King Chulalongkorn Memorial

7 Hospital, Rama 4 Road, Patumwan, Bangkok 10330, Thailand.

8 Tel: +66814888549

9 E-mail: prof.areerat@gmail.com, areerat.su@chula.ac.th

10 This study received a grant from Ratchadapiseksomphot

11 Endowment Fund, Faculty of Medicine, Chulalongkorn

12 University, Bangkok, Thailand.

rESWT & Injection for myofascial pain measured with Elastic index

1 The preliminary data was presented at the 9th International
2 Society of Rehabilitation Medicine Congress in 2015 and
3 published as the abstract in Annals of Physical medicine and
4 Rehabilitation 61 e2 20.

5 The authors declare no conflicts of interest in this work.

6

7

ABSTRACT

8 **Purpose:** To compare the efficacy of radial extracorporeal shockwave therapy (rESWT) versus injection
9 of 1% lidocaine for active myofascial trigger points (MTPs) at upper trapezius muscle (UTM) objectively
10 with elastic index analysis.

11 **Patients and methods:** A prospective, randomised, single-blinded clinical trial was done. 60 patients with
12 active MTPs of UTM were randomised to receive either rESWT (n = 30); three rESWT sessions; one
13 session per week; 2000 rESWT impulses per session; positive energy flux density = 0.10 mJ/mm²) or 1%
14 lidocaine (4 ml) injection (n = 30) (three injections; one injection per week). The outcome measure was

rESWT & Injection for myofascial pain measured with Elastic index

1 the elastic index of MTPs, visual analogue score (VAS score) of pain, and pressure pain threshold (PPT)
2 three weeks after baseline.

3 **Results:** Both rESWT and injection of 1% lidocaine resulted in statistically significant ($P < 0.05$) reduced
4 elastic index and VAS of pain of UTM and PPT significantly ($P < 0.05$) at three weeks after baseline. The
5 mean differences between rESWT and injection of 1% lidocaine showed no statistically significance.

6 **Conclusion:** Both rESWT and 1% lidocaine injection had efficacy for active MTPs of UTM measured with
7 elastic index, VAS of pain and PPT.

8 **Keywords:** myofascial trigger points (MTPs), radial extracorporeal shock wave therapy (rESWT) , 1%
9 lidocaine injection, elastic index, visual analogue score (VAS score) of pain, pressure pain threshold
10 (PPT).

11

12

13 **List of abbreviations**

14• MTP, myofascial trigger point;

15• MPS, myofascial pain syndrome;

16• rESWT, radial shock wave therapy;

17• UTM, upper trapezius muscles

18• EI, elastic index;

19• VAS, visual analog scale;

rESWT & Injection for myofascial pain measured with Elastic index

1 PPT, pressure pain threshold;

2 NDI, neck disability index

3 **Highlights**

4 • Extracorporeal shockwave therapy (ESWT) is an alternative to 1% lidocaine injection for
5 myofascial trigger points (MTPs).

6 • Elastic index provides evidence for the quantitative assessment of MTPs.

7

rESWT & Injection for myofascial pain measured with Elastic index

11. Introduction

2 Myofascial pain syndrome (MPS) characterized by local and referred pain and/or autonomic phenomena
3 due to the myofascial trigger points (MTrPs). Several hypotheses explain the pathophysiology of MTrPs, with
4 the most accepted hypothesis being integrated trigger point hypothesis¹⁻⁸, believing that MTrP is the result of
5 sarcomere sustained contraction caused by acetylcholine over release at the neuromuscular junction from
6 overuse or muscle injury. Strong muscle contraction is a process by pressing the blood vessels from the
7 constricted muscle. Leading to local ischemia, which stimulates secretion of vasoneuroactive, there is a lot of
8 pain, especially in the MTrP site. This neurologic inflammatory effect coincides with tissue swelling, resulting
9 in an increase in energy crises that impede calcium ingestion to the sarcoplasmic reticulum, thus stopping
10 the sarcomere shrinkage. A new cycle exists if there is a stimulating factor. There are currently several
11 studies explaining the biologic al properties of MTrP by microanalytic intramuscular biochemical
12 analysis. Many altered biochemical properties were found in MTrP, including those in active muscle regions.
13 There was an acidic pH in MTrP more than in normal muscle region. Similar to inflammatory markers,
14 bradykinin, substance P, tumor necrosis factor, interleukin (IL) -1, IL-6, IL-8, CGRP, serotonin, and
15 norepinephrine Higher concentrations were found in Active MTrP than in latent MTrP or in normal muscle.¹⁻⁸

16 Active MTPs are characterized by eliciting spontaneous pain and, when palpated, causing pain,
17 referred pain, and motor or autonomic symptoms, including limited range of motion, muscle weakness, and
18 loss of coordination.¹⁻⁸ In contrast, latent MTPs may display all the symptoms of active MTPs to a lesser
19 degree, but only upon palpation and/or compression.^{7,6} Recently, it was argued that the diagnosis of MTPs

rESWT & Injection for myofascial pain measured with Elastic index

1 is more complicated.^{1-3, 6,7} There are well-constructed reviews published on the agreement of the inter- and
2 intra-rater reliability in the manual palpation of MTPs.^{8,9} Recently, a systematic review and meta-analysis
3 found small sample sizes of the studies and disagreed in the reliability.¹⁰ There are more objective diagnoses
4 and monitoring the treatment success of MTPs MTPs. Elastic index appears promising in this regard.¹¹⁻¹⁴
5 MTrPs at the superficial muscles as upper trapezius muscle can be visualized using ultrasound imaging.

6 Several therapies have been proposed for MTPs, including trigger point injection with anesthetics,
7 corticosteroids or botulinum toxin, dry needling, massage, stretching, electrical stimulation, laser therapy,
8 and ultrasound therapy. The common goal of these therapies is to reduce muscle stiffness and pain, and
9 improve metabolism in the hypercontracted MTP region.¹⁻⁵

10 Recently, extracorporeal shock wave therapy (ESWT) has become an alternative in the treatment of
11 MTPs.¹⁵⁻²⁵ From a recent systematic review and meta-analysis²⁶, ESWT appears to be correlated with
12 greater pain relief compared with sham ESWT or ultrasound in patients with MPS of the trapezius. However,
13 the number of included trials was still small, and the studies were heterogeneous. Additional high-quality
14 clinical trials with large sample sizes, and importantly, objective measurement is needed to analyze the effect
15 of ESWT.

16 The aim of the present study was to test the hypothesis that rESWT, as performed in the present study,
17 is as effective and safe as 1% lidocaine injection in the management of MTPs of UTM, and elastic index is a
18 useful quantitative and objective measurement for monitoring treatment success in restoration of normal
19 muscle laxity. For a better understanding of the mechanisms of both RSWT and MTrP injection towards

rESWT & Injection for myofascial pain measured with Elastic index

1 MTrP.

22. Materials and Methods

3 Study design

4 This research was a randomized, single-blinded, parallel group trial from January 2016 through June 2019.

5 The study conformed to the principles of the Declaration of Helsinki. The study was approved by the

6 Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Protocol

7 No.: 222/57; date of approval by the ethics committee: September 17, 2015) before starting the study, and

8 was carried out in accordance with the World Medical Association (WMA) Declaration of Helsinki.²⁷ It has

9 been registered with the Thai Clinical Trials Registry (www.clinicaltrials.in.th; Identifier TCTR20160330003).

10 All patients were allowed to withdraw informed consent to participate in the present study at any time. There

11 was no commercial sponsorship in this study.

12 Participants

13 The patients with MPS, diagnosis was based on Simon's criteria^{4,5} for eligibility to be enrolled in the present

14 study. The inclusion criteria were as follows: 1) age between 20 and 25 years; 2) diagnosis of only one

15 active upper trapezius myofascial trigger point on either the left or right side; 3) mild to moderate pain

16 intensity at baseline (pain on the Visual Analog Scale between 3 and 6); 4) availability to attend the hospital

17 during the treatment and follow-up assessments; and 5) willingness to sign the informed consent form. The

18 exclusion criteria were as follows: 1) fixed contractures or deformities of the shoulder and neck; 2) diseases

19 of bones and joints; 3) clinical signs of myopathy and neuropathy; 4) treatment of upper trapezius myofascial

rESWT & Injection for myofascial pain measured with Elastic index

1 trigger points with extracorporeal shock waves, dry needling, injection of Botulinum neurotoxin, local
2 anesthesia, drugs, or any other treatment during a period of three months before inclusion in the present
3 study; 5) previous surgery of the shoulder and neck; 6) epilepsy; 7) intellectual disability ; 8) intellectual
4 disability; 9) infection, tumor, ulcer, or skin diseases at the site of therapy application; 10) serious blood
5 dyscrasia; 11) blood-clotting disorders; 12) treatment with oral anticoagulants.

6 Randomization and blinding

7 The Consolidated Standards of Reporting Trials (CONSORT) flow chart is shown in figure 1. Depending on a
8 computer-generated random numbers list, eligible participants were randomly separated into the rESWT
9 group or the lidocaine injection group. The outcome assessor in sonoelastography was blinded to group
10 division and did not take part in implementing interventions. The statistician was unaware of the group
11 assignment as well.

12 Interventions

13 All rESWTs were given by a single, experienced physiatrist. rESWT was conducted using the Swiss
14 DolorClast (Electro Medical Systems, Nyon, Switzerland) and the EvoBlue handpiece with a 15-mm
15 applicator. Each patient received one rESWT session per week for three weeks, with 2000 rESWT waves
16 per session with the air pressure of the device was set at 2.5 bar, a frequency of 12 Hz, resulting in a positive
17 energy flux density (EFD) of 0.10 mJ/mm². Participants assigned to the lidocaine injection group were
18 injected by the same experienced physiatrist with 2 ml of 1% lidocaine at the trigger point confirmed by a
19 local twitch response.

rESWT & Injection for myofascial pain measured with Elastic index

1 As part of the treatment program, all participants, regardless of the group, were educated on a simple home
2 exercise program for the first visit. The program comprised a single UTM stretching exercise. The patients
3 received the video file of the UTM stretching exercise procedure displayed on their mobile phones. The
4 patients were asked to perform 10 sessions twice a day.

5 Assessment

6 Outcome measures included muscle elasticity, pain with the Visual Analog Scale (VAS) and pressure pain
7 threshold (PPT), and neck disability index (NDI). Evaluation was performed at baseline (T1), immediately
8 after the first session (T2), before the second session (i.e., one week after baseline; T3), and one week after
9 the third session (i.e., four weeks after baseline; T4). To evaluate the immediate effects, the patients were
10 assessed immediately 15-30 min after the first treatment. The examiners were blinded to the group
11 allocation.

12 The muscle elasticity

13 It was assessed by elastic index using a LOGIQ S7 Expert ultrasound scanner (GE Healthcare, Little
14 Chalfont, UK), ML6-15 high-frequency linear ultrasound transducer (GE Healthcare), and dedicated
15 quantitative software (Elasto-Q). To this end, the head of the patient was placed in a neutral position and the
16 upper trapezius muscle was identified using two-dimensional (2D) ultrasound mode. The examiner then
17 performed elastic index of UTM strictly following the equipment guidelines for standardization of the
18 technique by rhythmic tissue compression and decompression¹¹⁻¹⁴, with the accuracy of this maneuver
19 automatically checked by the LOGIQ S7 Expert ultrasound scanner. Finally, elastograms were generated

rESWT & Injection for myofascial pain measured with Elastic index

1 using Elasto-Q software that simultaneously recorded and visualized 2D ultrasound and elastogram images
2 of the same region of interest (ROI). After setting the UTM layer as the ROI and localization of the best
3 sinusoidal compression, three ROIs on MTrPs in the upper trapezius muscle were selected for calculating
4 the mean elasticity index as figure 2 and figure 3. All the sonoelastography data were analyzed by a blinded
5 researcher who was an expert ultrasonographer.

6 Visual Analog Scale (VAS)

7 Pain intensity was assessed using the VAS. The VAS is 10 cm long, anchored with the words "no pain" and
8 "worst pain imaginable" at the opposite ends.¹⁵ The mean reduction in VAS of 2.0 cm represents a clinically
9 significant difference in pain severity that corresponds to effective treatments.¹⁶ Participants were requested
10 to mark a point along the scale that best represented the level of pain experienced.

11 Pressure Pain Threshold (PPT)

12 The pressure pain threshold was measured by a digital pressure algometer for the least amount of pressure
13 needed to provoke pain.¹⁷ The procedure was performed with an algometer (Model PTH AF2; Pain
14 Diagnostics and Thermography, Great Neck, NY), by placing the rubber tip area perpendicular to the MTrPs
15 at a pressing rate of 1 kg/s.¹⁸ The compression stopped immediately when the patients began to feel pain..
16 Three repetitive measurements at intervals of 30 s were performed at the same point, and then the average
17 value was calculated.

18 The Neck Disability Index (NDI)

rESWT & Injection for myofascial pain measured with Elastic index

1 The Neck Disability Index (NDI) is a widely used self-rating scale to evaluate the impact of pain on daily
2 activities. It included 10 parts: pain intensity, personal care, lifting objects, reading, headache, concentration,
3 work, driving, sleeping, and entertainment. The minimum detectable change is 5.0 points, and the minimum
4 clinically important difference is in the range of 3.5-5.0. points.¹⁹

5 Side effects

6 Adverse reactions defined as any unexpected events that occurred during the trial were noted and recorded.

7 Statistical analysis

8 All data were statistically analyzed using the Statistical Program for Social Sciences (SPSS) version 17
9 (SPSS Inc., Chicago), and P values of <.05 were considered statistically significant. Baseline characteristics
10 between groups were compared using independent t-tests or Mann-Whitney U tests for continuous variables
11 (depending on normality) and chi-square tests for categorical variables. The outcome measures were
12 submitted to a 2x3 repeated measures analysis of variance with time (baseline, T1,T2,T3, and T4) as the
13 within-subject factor and group (ESWT or 1%lidocaine) as the between-subject factor. The Greenhouse-
14 Geisser correction was used when the sphericity assumption was violated. Bonferroni correction was applied
15 to adjust the significance levels. Unless otherwise stated, all values are reported as mean \pm SD.
16 The VAS score was chosen as the primary outcome measure. The study was powered to detect 2-cm
17 differences in a 10-cm VAS between the ESWT and 1% lidocaine injection groups with an SD of 2 cm, which
18 was adjusted based on the results of a previous publication.³¹ In consideration of a type I error rate of 5%, a
19 power of 80%, and at least 10% losses to follow-up, 25 patients were required per group at baseline. To

rESWT & Injection for myofascial pain measured with Elastic index

1 improve the reliability of our study, we increased the sample size to 30 patients per group.

23. Results

3 Characteristics of the patients

4 Patients were considered for participation in the present study according to the inclusion and exclusion
5 criteria. The flow of patients is shown in Figure 1.²⁰. After the diagnosis was confirmed, five out of the 65
6 patients assessed for eligibility were excluded. For the remaining 60 patients, a thorough explanation of
7 radial extracorporeal shock wave therapy (rESWT) and 1% lidocaine for MTPs as well as the potential risks,
8 benefits, and outcomes, took place. After making an informed decision, the patients were enrolled in the
9 present study (n = 60), allocated to ESWT group 30 patients and 1%lidocaine group 30 patients . None of
10 the patients were lost to follow-up before the second session (i.e., one week after baseline) and one week
11 after the third session (i.e., three weeks after baseline), resulting in full analysis of all patients at all follow-up
12 examinations.

13 Outcomes

14 There was a statistically significant improvement in the mean elastic index of UTM, VAS of pain, PPT at
15 UTM, and NDI in the 1%xylocain group compared to those in the rESWT group at T2 and T3 at $p < 0.05$, as
16 displayed in Table 2 and compared to baseline in both groups at $p < 0.001$, as displayed in Table 3. All
17 outcome measurements were very similar in the 1%lidocaine and rESWT groups both before (T1) and no
18 statistically significant difference at one week after the third session (T4) at $P < 0.05$.

19 Adverse effects

rESWT & Injection for myofascial pain measured with Elastic index

- 1 Pain and reddening of the skin were reported in a few cases, but did not lead to dropping out of the patients.
- 2 No persistent adverse effects were observed.

34. Discussion

4 The rESWT for MTPs of UTM as performed in the present study (three rESWT sessions, one session per
5 week, 2000 rESWs per session with EFD₊ of 0.10 mJ/mm²) was the least session, similar to some previous
6 studies.^{22,28,29,30} resulted in a statistically significant improvement in (i) mean elastic index of UTM, (ii) mean
7 VAS score, (iii) mean pressure pain threshold (PPT), and (iv) mean neck disability index (NDI) at one week
8 and 4 weeks to baseline in the ESWT group, which is in line with previous studies.^{22,28,29,30} The intergroup
9 comparison with the 1%lidocaine group revealed statistically significantly better results than the rESWT
10 group at T2 and T3, which was not in line but not statistically significant at T4 at p<0.05, which is in line with
11 a previous study that compared with the dry needle.³⁰ The pathophysiologic mechanisms underlying MTrPs
12 development were still not clear. The current data proved that ESWT was at least as effective as
13 1%lidocaine in pain relieving and function restoration for MPS patients after the completion of the therapy 3
14 sessions , once per week for 3 weeks.

15
16 ESWT has become one of the evidence based modalities for MPS in recent years.²¹⁻³² Twenty-two types of
17 extracorporeal shock waves (ESWs) are used in medical therapy, namely focused extracorporeal shock
18 waves (fESWs) and rESWs.³²⁻³⁶ The positive pressure amplitude is followed by a low tensile amplitude of a
19 few microseconds, which can generate cavitation.³³⁻³⁷ They are further characterized by a short life cycle of

rESWT & Injection for myofascial pain measured with Elastic index

1 approximately 10-20 μ s and a broad frequency spectrum. Focused ESWs differ from rESWs in the
2 penetration depth into the tissue, some physical characteristics, and the technique for generating them.³³⁻³⁶

3 The reduction in the mean VAS score after rESWT found in the present study is in line with the results of
4 earlier studies on ESWT for MTPs.²¹⁻³¹ The outcome measures in this study are in line with other studies in
5 PPT^{21-23,25,27,29} and NDI.^{21,25,26,28,29} There are only one²⁰ of these studies²¹⁻³¹ that elastic index was applied
6 to monitor treatment success of ESWT for MTPs.

7 Elastic index as performed in the present study showed almost identical mean elastic indexes of UTM
8 (difference smaller than 10%) between the rESWT and sham rESWT groups at baseline. The elastic indexes
9 of UTM of all patients in the rESWT group decreased as a result of rESWT, whereas elastic indexes of UTM
10 in all patients in the Sham rESWT group showed only very limited changes between baseline and three
11 weeks after baseline. Accordingly, sono elastography as performed in the present study was useful for
12 monitoring treatment success of rESWT for MTPs of UTM, which was in line with the previous study.²⁹

13 Various hypotheses about the etiology and pathophysiology of MTPs were proposed,¹⁻⁸ However, so far it
14 has not been possible to formulate an integrated concept answering the questions what initiates the
15 formation of MTPs, sustains MTPs, causes MTPs to be painful, and will make MTPs disappear.¹⁻⁸ The
16 difficulties are further exacerbated by the lack of an animal model for myofascial pain that could be used to
17 test mechanistic hypotheses.¹⁻⁸ Unfortunately, the results of the present study do not help to improve this
18 situation. This is due to the fact that the changed elasticity of UTM after rESWT can only be one of several
19 mechanisms mediating the positive effects of rESWT on MTPs, and may in complex combination with the

rESWT & Injection for myofascial pain measured with Elastic index

1 following mechanisms leading to reduction of pain: (i) rESWT was shown to improve the neck range of
2 motion in a previous study²² and neck disability index (NDI) in this study and in line with previous studies.
3^{21,25,26,28,29} The underlying mechanisms are unknown and may involve mechanical separation of actin and
4 myosin filaments. However, rESWT did not change the mean elastic index of UTM immediately after
5 treatment in the present study. (ii) Exposure of muscles to rESWs may induce a transient dysfunction of
6 nerve conduction at neuromuscular junctions, as was observed in the gastrocnemius muscles of rats for six
7 weeks after exposure³⁸, (iii) Active MTPs may contain high amounts of substance P³⁹, one of the body's
8 neurotransmitters for pain and heat.⁴⁰ Exposure of tissue to ESWs can reduce substance P.⁴¹ (iv) One
9 cannot rule out that according to the gate control theory of pain⁴², the mechanical impact of rESWs on large-
10 diameter afferent fibers modulates the spinal dorsal horn transmission of nerve impulses from small-diameter
11 afferent fibers to spinal cord transmission cells. (v) Lubricin, a mucinous glycoprotein, facilitates the
12 movement of tendon gliding against the surrounding tissues.⁴³, and is also found on fasciae.⁴⁴ Flexor
13 tendons from canine forepaws that had been suspended without weight-bearing for 21 days showed a 40%
14 reduction of lubricin expression compared to contralateral forepaws that had been allowed free motion.⁴⁵
15 Reduced lubricin expression also plays a role in the pathophysiology of MTPs, ESWT may exert its positive
16 effect by its known stimulating effect on lubricin expression in septa.⁴⁴ (vi) Improved muscular
17 microcirculation after repetitive ESWT⁴⁶ may be another mechanism that may result in pain relief after ESWT
18 for MTPs of UTM. Taken together, identification of the exact molecular and cellular mechanisms of action of
19 rESWT on MTPs will require muscle biopsies and/or microdialysis^{39,47} in future studies on humans.

rESWT & Injection for myofascial pain measured with Elastic index

1 A systematic review in 2012⁴⁸, including five RCTs comparing dry needling versus 1% lidocaine injection
2 concluded that although no significant difference was observed between the two methods, there were
3 interesting patterns favoring 1% lidocaine injection immediately after injection and dry needling at 3–6
4 months after treatment. However, another meta-analysis in 2013⁴⁹ revealed slightly different results: 1%
5 lidocaine injection was more effective than dry needling on pain improvement immediately and at 4 weeks
6 follow-up.

7 The MPS is currently considered a complicated neuromuscular disorder involving both peripheral and central
8 mechanisms. When MTrPs were left untreated or inadequately treated, the continuous pain induced by
9 hyperirritable spots would send persistent impulses via afferent nerves to the spinal cord, which further
10 developed into the spinal segmental sensitization.¹⁻⁸ Thus, desensitization of MTrPs should be the goal of
11 developing a durable and effective treatment. A 1%lidocaine injection is the gold standard to confirm typical
12 localized twitching response and referred pain when needles were applied, which ESWT might be helpful for
13 the clinical diagnosis of MTrPs. To date, there is still no standard guideline defining the optimal parameters
14 of EFD or treatment course for ESWT. In this study, the ESWT revealed a delay effect of the elastic index,
15 VAS, PPT, and NDI when compared with 1%lidocaine injection at T2 and T3.

16 The rESWT has the following advantages over 1%lidocaine injection. First, the rESWT is noninvasive, free
17 from skin infection, and is simple to operate in an outpatient environment. However, 1% lidocaine injection
18 carries potential risks of significant adverse events, such as penetrating the lungs and blood vessel injuries,
19 which choose ultrasound guidance for prevention of these serious adverse effects. Second, the rESWT could

rESWT & Injection for myofascial pain measured with Elastic index

1 be applied to a relatively larger surface of interest (including the taut band and surrounding tissue) by
2 adjusting the probe location. ESWT usually induces microscopic changes within cells via
3 mechanotransduction effects and promotes the conversion of mechanical pressure into molecular signals.
4 Moreover, the regenerative effect of rESWT can enhance muscle properties. Third, 1% lidocaine injection
5 carries mild side effects such as bleeding per skin from the needle, dizziness, or allergy from a 1% lidocaine
6 effect. Although it might require a higher cost than 1% lidocaine injection, the ESWT could be an alternative
7 option for MTrPs treatment considering patient compliance.

8 Study limitation

9 Some limitations of this study should be acknowledged. First, the subjective bias since the patients were not
10 blinded to the treatments. Second, no subgroups with different intensities, intervals, and frequencies of
11 rESWT because the dose-dependent manner of total energy might influence the therapeutic effects and
12 cost-effectiveness. The identification of optimal regimens and cost-effective analysis should be an important
13 topic in the future. Third, the current results should be interpreted based on noninferior trial design, and the
14 false-negative possibility (discriminating capacity 80%) should be considered. Fourth, the target population
15 was patients aged 20-25 years, which excluded MPS associated with degenerative joint disorders
16 commonly found in aging. The applications and success of rESWT will be limited to young patients with the
17 inclusion and exclusion criteria.

185. Conclusion

19 rESWT, as applied in the present study, is also efficient as the gold standard for 1% lidocaine injection for

rESWT & Injection for myofascial pain measured with Elastic index

1 treating patients suffering from MTPs of UTM after 3 sessions. Ultrasound elastography, as applied in the
2 present study, appears useful for objectively monitoring treatment success in 1% lidocaine injection and
3 rESWT for MTPs of UTM.

Acknowledgments

5 This study was supported by a grant from Ratchadapiseksomphot Endowment Fund, Faculty of Medicine,
6 Chulalongkorn University, Bangkok, Thailand.

7 The preliminary data was presented at the 9th International Society of Rehabilitation Medicine Congress in
8 2015 and published as the abstract in *Annals of Physical medicine and Rehabilitation* 61 e2 20.

Disclosure

10 The authors report no conflicts of interest in this work.

116. References

- 12 1. Shah JP, Thaker N, Heimur J, Aredo JV, Sikdar S, Gerber L. Myofascial Trigger Points Then and Now: A
13 Historical and Scientific Perspective. *PM R*. 2015 Jul;7(7):746-761.
- 14 2. Fernández-de-Las-Peñas C, Nijs J. Trigger point dry needling for the treatment of myofascial pain
15 syndrome: current perspectives within a pain neuroscience paradigm *J Pain Res*. 2019 Jun 18;12:1899-
16 1911.
- 17 3. Do TP, Heldarskard GF, Kolding LT, Hvedstrup J, Schytz HW. Myofascial trigger points in migraine and
18 tension-type headache. *J Headache Pain*. 2018 Sep 10;19(1):84. doi: 10.1186/s10194-018-0913-8.
- 19 4. Shah JP, Thaker N, Heimur J, Aredo JV, Sikdar S, Gerber L. Myofascial Trigger Points Then and Now: A

rESWT & Injection for myofascial pain measured with Elastic index

- 1 Historical and Scientific Perspective. PM R. 2015 Jul;7(7):746-761.
- 2 5. Simons DG, Travell JG, Simons LS. Travell & Simons' Myofascial Pain and Dysfunction: The Trigger
3 Point Manual (2-Volume Set), Lippincott Williams & Wilkins, Philadelphia, PA, USA, 2nd edition, 1998.
- 4 6. Gerwin RD. Diagnosis of myofascial pain syndrome. Phys Med Rehabil Clin N Am 2014 May;25(2):341-
5 55.
- 6 7. Eloqayli H. Subcutaneous accessory pain system (SAPS): A novel pain pathway for myofascial trigger
7 points. Med Hypotheses 2018 Feb; 111:55-57.
- 8 8. Celik D, Mutlu EK. Clinical implication of latent myofascial trigger point.
9 Curr Pain Headache Rep 2013 Aug;17(8):353. doi: 10.1007/s11916-013-0353-8
- 10 9. Lucas N, Macaskill P, Irwig L, et al. Reliability of physical examination for diagnosis of myofascial trigger
11 points: a systematic review of the literature. Clin J Pain. 2009; 25:80–89.
- 12 10. Myburgh C, Larsen AH, Hartvigsen J. A systematic, critical review of manual palpation for identifying
13 myofascial trigger points: evidence and clinical significance. Arch Phys Med Rehabil. 2008;89:1169–
14 1176.
- 15 11. Rathbone ATL, Grosman-Rimon L, Kumbhare DA. Interrater Agreement of Manual Palpation for
16 Identification of Myofascial Trigger Points: A Systematic Review and Meta-Analysis. Clin J Pain 2017
17 Aug;33(8):715-729.
- 18 12. Salavati M, Akhbari B, Ebrahimi Takamjani I, Ezzati K, Haghighatkhah H . Reliability of the Upper
19 Trapezius Muscle and Fascia Thickness and Strain Ratio Measures by Ultrasonography and

rESWT & Injection for myofascial pain measured with Elastic index

- 1 Sonoelastography in Participants With Myofascial Pain Syndrome. *J Chiropr Med.* 2017 Dec;16(4):316-
- 2 323.
- 3 13. Sikdar S, Shah JP, Gebreab T, Yen RH, Gilliams E, Danoff J, Gerber LH. Novel applications of
- 4 ultrasound technology to visualize and characterize myofascial trigger points and surrounding soft tissue.
- 5 *Arch Phys Med Rehabil.* 2009 Nov;90(11):1829-38.
- 6 14. Ballyns JJ, Shah JP, Hammond J, Gebreab T, Gerber LH, Sikdar S.J Objective sonographic measures for
- 7 characterizing myofascial trigger points associated with cervical pain. *Ultrasound Med.* 2011
- 8 Oct;30(10):1331-40.
- 9 15. Turo D, Otto P, Hossain M, Gebreab T, Armstrong K, Rosenberger WF, Shao H, Shah JP, Gerber LH,
- 10 Sikdar S. Novel Use of Ultrasound Elastography to Quantify Muscle Tissue Changes After Dry Needling
- 11 of Myofascial Trigger Points in Patients With Chronic Myofascial Pain. *J Ultrasound Med.* 2015
- 12 Dec;34(12):2149-61.
- 13 16. Price DD, Bush FM, Long S, et al: A comparison of pain measurement characteristics of mechanical
- 14 visual analogue and simple numerical rating scales. *Pain* 1994;56:217-26
- 15 17. Todd KH, Funk JP: The minimum clinically important difference in physician-assigned visual analog pain
- 16 scores. *Acad Emerg Med* 1996;3:142-6
- 17 18. Fischer AA: Pressure algometry over normal muscles. Standard values, validity and reproducibility of
- 18 pressure threshold. *Pain* 1987;30:115-26

rESWT & Injection for myofascial pain measured with Elastic index

- 1 19. Pool JJ, Ostelo RW, Hoving JL, et al: Minimal clinically important change of the Neck Disability Index and
2 the Numerical Rating Scale for patients with neck pain. *Spine (Phila Pa 1976)* 2007;32:3047-51
- 3 20. Schulz KF, et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised
4 trials. *BMC Med.* 2010. PMID: 20334633
- 5 21. Cho YS, Park SJ, Jang SH, Choi YC, Lee JH, Kim JS. Effects of the combined treatment of
6 extracorporeal shock wave therapy (ESWT) and stabilization exercises on pain and functions of patients
7 with myofascial pain syndrome. *J Phys Ther Sci* 2012;24:1319-23.
- 8 22. Jeon JH, Jung YJ, Lee JY, et al. The effect of extracorporeal shock wave therapy on myofascial pain
9 syndrome. *Ann Rehabil Med* 2012; 36:665-74.
- 10 23. Ji HM, Kim HJ, Han SJ. Extracorporeal shock wave therapy in myofascial pain syndrome of upper
11 trapezius. *Ann Rehabil Med* 2012;36:675-80.
- 12 24. Gur A, Koca I, Karagullu H, Altindag O, Madenci E. Comparison of the efficacy of ultrasound and
13 extracorporeal shock wave therapies in patients with myofascial pain syndrome: A randomized controlled
14 study. *J Musculoskelet Pain* 2013;21:210-6.
- 15 25. Lee JH, Han EY. A comparison of the effects of PNF, ESWT, and TPI on pain and function of patients
16 with myofascial pain syndrome. *J Phys Ther Sci* 2013;25:341-4.
- 17 26. Taheri P, Vahdatpour B, Andalib S. Comparative study of shock wave therapy and Laser therapy effect in
18 elimination of symptoms among patients with myofascial pain syndrome in upper trapezius. *Adv Biomed*
19 *Res* 2016;5:138.

rESWT & Injection for myofascial pain measured with Elastic index

- 1 27. Akturk S, Kaya A, Cetintas D, et al. Comparison of the effectiveness of ESWT and ultrasound treatments
2 in myofascial pain syndrome: randomized, sham-controlled study. *J Phys Ther Sci* 2018;30:448-53.
- 3 28. Kiraly M, Bender T, Hodosi K. Comparative study of shockwave therapy and low-level laser therapy
4 effects in patients with myofascial pain syndrome of the trapezius. *Rheumatol Int* 2018;38:2045-52./
- 5 29. Luan S, Zhu ZM, Ruan JL, et al. Randomized trial on comparison of the efficacy of extracorporeal shock
6 wave therapy and dry needling in myofascial trigger points. *Am J Phys Med Rehab* 2019;98:677-84.
- 7 30. Manafnezhad J, Salahzadeh Z, Salimi M, Ghaderi F, Ghojazadeh M. The effects of shock wave and dry
8 needling on active trigger points of upper trapezius muscle in patients with non-specific neck pain: a
9 randomized clinical trial. *J Back Musculoskelet Rehabil* 2019;32:811-8.
- 10 31. Park KD, Lee WY, Park MH, Ahn JK, Park Y. High- versus low-energy extracorporeal shock-wave therapy
11 for myofascial pain syndrome of upper trapezius: A prospective randomized single blinded pilot study.
12 *Medicine (Baltimore)*. 2018 Jul;97(28):e11432.
- 13 32. Zhang Q, et al . Efficacy of Extracorporeal Shockwave Therapy on Pain and Function in Myofascial Pain
14 Syndrome of the Trapezius: A Systematic Review and Meta-Analysis. *Arch Phys Med Rehabil*.
15 2020. PMID: 32234411 Review.
- 16 33. Schmitz C, Császár NB, Milz S, Schieker M, Maffulli N, Rompe JD, Furia JP. Efficacy and safety of
17 extracorporeal shock wave therapy for orthopedic conditions: a systematic review on studies listed in the
18 PEDro database. *Br Med Bull*. 2015;116(1):115-38.

rESWT & Injection for myofascial pain measured with Elastic index

- 1 34. Speed C. A systematic review of shockwave therapies in soft tissue conditions: focusing on the evidence.
2 Br J Sports Med 2014;48:1538–42.
- 3 35. Wang CJ.Extracorporeal shockwave therapy in musculoskeletal disorders J Orthop Surg Res 2012 Mar
4 20; 7:11.doi: 10.1186/1749-799X-7-11.
- 5 36. Ioppolo F, Rompe JD, Furia JP, Cacchio A. Clinical application of shock wave therapy (SWT) in
6 musculoskeletal disorders . Eur J Phys Rehabil Med. 2014 Apr;50(2):217-30.
- 7 37. Császár NB, Angstman NB, Milz S, Sprecher CM, Kobel P, Farhat M, Furia JP, Schmitz C. Radial Shock
8 Wave Devices Generate Cavitation. PLoS One. 2015 Oct 28;10(10):e0140541. doi:
9 10.1371/journal.pone.0140541. eCollection 2015.
- 10 38. Kenmoku T, Ochiai N, Ohtori S, Saisu T, Sasho T, Nakagawa K, Iwakura N, Miyagi M, Ishikawa T,
11 Tatsuoka H, Inoue G, Nakamura J, Kishida S, Saito A, and Takahashi K. Degeneration and recovery of
12 the neuromuscular junction after application of extracorporeal shock wave therapy. J Orthop Res 2012
13 Oct;30(10):1660-5.
- 14 39. Shah J P, Danoff J V, Desai M J, Parikh S, Nakamura LY, Phillips TM, Gerber LH. Biochemicals
15 associated with pain and inflammation are elevated in sites near to and remote from active myofascial
16 trigger points. Arch Phys Med Rehabil 2008 Jan;89(1):16-23.
- 17 40. Snijdelaar DG, Dirksen R, Slappendel R, Crul BJ. Substance P. Eur J Pain 2000;4(2):121-35.
- 18 41. Maier M, Averbek B, Milz S, Refior HJ, Schmitz C. Substance P and prostaglandin E2 release after
19 shock wave application to the rabbit femur. Clin Orthop Relat Res 2003 Jan;(406):237-45.

rESWT & Injection for myofascial pain measured with Elastic index

- 1 42. Melzack R, Wall PD "Pain mechanisms: A new theory" *Science* 1965 Nov 19;150(3699):971-9.
- 2 43. Sun Y, Berger EJ, Zhao C, An KN, Amadio PC, Jay G. Mapping lubricin in canine musculoskeletal
3 tissues. *Connect Tissue Res* 2006;47(4):215-21.
- 4 44. Zhang -D, Kearney CJ, Cheriyan T, Schmid TM, Spector M. Extracorporeal shockwave-induced
5 expression of lubricin in tendons and septa. *Cell Tissue Res* 2011 Nov;346(2):255-62.
- 6 45. Sun YL, Zhao C, Jay GD, Schmid TM, An KN, Amadio PC. Effects of stress deprivation on lubricin
7 synthesis and gliding of flexor tendons in a canine model in vivo. *J Bone Joint Surg Am* 2013 Feb
8 6;95(3):273-8.
- 9 46. Kisch T, Wuerfel W, Forstmeier V, Liodaki E, Stang FH, Knobloch K, Mailaender P, Kraemer R. Repetitive
10 shock wave therapy improves muscular microcirculation. *J Surg Res* 2016 Apr;201(2):440-5.
- 11 47. Waugh CM, Morrissey D, Jones E, Riley GP, Langberg H, Screen HR. In vivo biological response to
12 extracorporeal shockwave therapy in human tendinopathy. *Eur Cell Mater* 2015 May 15;29:268-80.
- 13 48. Ong J, Claydon LS. The effect of dry needling for myofascial trigger points in the neck and shoulders: a
14 systematic review and meta-analysis. *J Bodyw Mov Ther.* 2014;18(3):390–398.
- 15 49. Kietrys DM, Palombaro KM, Azzaretto E, et al. Effectiveness of dry needling for upper-quarter myofascial
16 pain: a systematic review and meta-analysis. *J Orthop Sports Phys Ther.* 2013;43(9):620–634

17

18

19

rESWT & Injection for myofascial pain measured with Elastic index

1

2

3





Figure 1 Consolidated Standards of Reporting Trials flow chart.



Elasto

Time (s) :	Trace 1 :
0.01631	1.27157e+000
0.06477	1.28725e+000
0.11323	1.30000e+000
0.16168	1.32255e+000
0.21014	1.32451e+000
0.25859	1.31471e+000
0.30705	1.28039e+000
0.35550	1.29510e+000
0.40396	1.29118e+000
0.45242	1.28824e+000
0.50087	1.32647e+000
0.54933	1.32549e+000
0.59778	1.37157e+000
0.64624	1.35686e+000
0.69470	1.37255e+000
0.74315	1.37549e+000
0.79161	1.37451e+000
0.84007	1.37353e+000
0.93698	1.30392e+000
1.03389	1.31471e+000
1.13080	1.36373e+000
1.17925	1.26078e+000
1.22771	1.25588e+000
1.27617	1.28235e+000
1.32462	1.28431e+000
1.37309	1.31863e+000
1.42154	1.28529e+000
1.46999	1.26961e+000
1.51845	1.30686e+000
1.56691	1.32059e+000
1.61536	1.31569e+000
1.66382	1.31961e+000
1.71227	1.31471e+000



Mean

**Elasticity Index
(EI)**

Table 1 Baseline characteristics of the patients

Characteristics	1% xylocaine (n=30)	rESWT (n=30)	Total (n=60)
Age (Y)	22.93 ± 1.03	23.05 ± 1.02	22.99 ± 1.00
Gender: Male: Female	12:18	13:17	25:35
BMI (kg/m ²)	23.36 ± 1.82	23.69 ± 1.37	23.58 ± 1.69
Elastic index	2.14 ± 0.23	2.19 ± 0.21	2.12 ± 0.23
VAS (cm)	5.45 ± 0.34	5.49 ± 0.39	5.47 ± 0.36
PPT (N/cm ²)	2.88 ± 0.20	2.82 ± 0.23	2.85 ± 0.22
NDI	33.34 ± 2.93	34.21 ± 3.69	34.03 ± 3.26

Table 2 Outcome measures at T1, T2, T3 and T4 (post hoc analysis)

Parameter (Time)	1% xylocaine		rESWT		1%xylocaine VS rESWT		
	Mean \pm SD	95% CI	Mean \pm SD	95% CI	Diff of Mean	P	95% CI
EI (T1)	2.14 \pm 0.23	1.84-2.21	2.19 \pm 0.21	2.08-2.23	0.148	0.571	0.101 - 0.170
EI (T2)	1.35 \pm 0.24	1.67-1.99	2.04 \pm 0.23	1.92-2.17	0.628	0.003*	0.471 -0.829
EI (T3)	1.18 \pm 0.20	0.74-1.34	1.41 \pm 0.26	1.26-1.55	0.371	0.034*	0.291-0.425
EI (T4)	0.93 \pm 0.15	0.78-1.21	1.01 \pm 0.13	0.96-1.15	0.131	0.856	0.092-.1.142
VAS (T1)	5.51 \pm 0.49	4.82-6.12	5.49 \pm 0.39	5.12-5.99	0.192	0.621	0.184- 0.254
VAS (T2)	4.11 \pm 0.24	3.78-4.36	5.19 \pm 0.21	4.79-5.44	1.314	0.041*	1.212-1.521
VAS (T3)	2.42 \pm 0.41	2.02-2.84	3.68 \pm 0.20	3.57-3.79	1.262	0.035*	1.103 -1.424
VAS (T4)	0.97 \pm 0.23	0.76-1.11	1.01 \pm 0.13	0.96-1.15	0.124	0.729	0.095 - 0.156

PPT (T1)	2.95 ± 0.21	2.70-3.23	2.82 ± 0.23	2.57-3.24	0.113	0.728	0.092 - 0.155
PPT (T2)	3.37 ± 0.16	3.11-3.64	2.99 ± 0.24	2.67-3.35	0.203	0.047*	0.189 – 0.228
PPT (T3)	3.74± 0.13	3.52-3.93	3.58 ± 0.20	3.44-3.71	0.293	0.041*	0.215 -- 0.304
PPT (T4)	3.98 ± 0.14	3.71-4.16	3.91 ± 0.13	3.47-4.15	0.112	0.045	0.102-0.146
NDI (T1)	33.34 ± 2.93	31.11- 35.12	34.21 ± 3.69	30.87- 37.44	1.247	0.619	1.196-1.292
NDI (T2)	No data	No data	No data	No data	No data	No data	No data
NDI (T3)	9.34 ± 2.67	7.84-12.24	17.29 ± 2.99	14.74- 19.84	6.912	0.041*	3.129-9.147
NDI (T4)	4.91 ± 0.25	4.13-5.46	5.01 ± 0.50	4.96-5.45	0.151	0.891	0.146-0.189

Abbreviations: CI, confidence interval; T1, baseline; T2, immediately after the first rESWT session ;

T3 , before the second rESWT session or one week after baseline ; T4, one week after the third

rESWT session or four weeks after baseline; EI, elastic index; VAS, visual analog scale; PPT,

pressure pain threshold; NDI, neck disability index

1 **Table 3 Within-subjects analysis of outcome measures (post hoc analysis)**

Parameter	Group	T1 and T3			T1 and T4		
		Diff of Mean	P	95% CI	Diff of Mean	P	95% CI
EI	1%xylocaine	0.97± 0.18	<0.001	0.67-1.21	1.17± 0.12	<0.001	1.01-1.35
	rESWT	0.64± 0.15	<0.001	0.59-0.84	1.13± 0.41	<0.001	0.98-1.52
VAS	1%xylocaine	2.21 ±0.24	<0.001	2.01-2.45	3.91±0.35	<0.001	3.54-4.31
	rESWT	1.78± 0.23	<0.001	1.85-2.32	4.01± 0.23	<0.001	3.87-4.27
PPT	1%xylocaine	0.84± 0.13	<0.001	0.63-1.24	1.02±0.13	<0.001	0.84-1.17
	rESWT	0.69±0.25	<0.001	0.42-0.92	1.19±0.22	<0.001	0.97-1.41
NDI	1%xylocaine	22.23± 2.47	<0.001	19.52-25.69	5.56± 0.94	<0.001	4.62-6.11
	rESWT	28.35±3.12	<0.001	25.13-31.68	28.89 ± 3.18	<0.001	24.41-32.15

2 Abbreviations: CI, confidence interval; T1, baseline; T2, immediately after the first rESWT session ; T3 ,
3 before the second rESWT session or one week after baseline ; T4, one week after the third rESWT
4 session or four weeks after baseline; EI, elastic index; VAS, visual analog scale; PPT, pressure pain
5 threshold; NDI, neck disability index

6

7